Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$176.4B
1,730M shares
52-week range
$81.97 – $137.49
38% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
3.9
EV / FCF (TTM)
23.7
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
www.abbott.comNo one on the platform currently holds ABT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,238,666 | $127.2M |
| Bridgewater Associatesas of 2026-03-31 | 117,051 | $12.0M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-15 | $0.6300 | 2026-08-17 |
| 2026-04-15 | $0.6300 | 2026-05-15 |
| 2026-01-15 | $0.6300 | 2026-02-13 |
| 2025-10-15 | $0.5900 | 2025-11-17 |
| 2025-07-15 | $0.5900 | 2025-08-15 |
| 2025-04-15 | $0.5900 | 2025-05-15 |
| 2025-01-15 | $0.5900 | 2025-02-14 |
| 2024-10-15 | $0.5500 | 2024-11-15 |
| 2024-07-15 | $0.5500 | 2024-08-15 |
| 2024-04-12 | $0.5500 | 2024-05-15 |
No one on the platform has traded ABT yet.
| 2024-01-11 | $0.5500 | 2024-02-15 |
| 2023-10-12 | $0.5100 | 2023-11-15 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.6% | 15.8% | 11.7% | — | — | — |
| Rev. Growth % | 5.7% | 5.1% | ||||
| Profit Margin % | 14.7% | 18.6% | 13.4% | |||
| Free Cash Flow Margin % | 16.7% | 16.5% | 15.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +4.4% on the P/E track.
At today's price, your expected annual return is +10.1% on the P/E track.
At today's price, your expected annual return is +14.3% on the P/E track.
Also held through funds
2 more books hold ABT indirectly · VTI 0.3% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $50.3B | +12.6% | $5.52 | $5.48–$5.57 | 18.7× | 18 |
| 2027 | $54.7B | +8.7% | $6.06 | $6.01–$6.18 | 17.0× | 18 |
| 2028 | $58.5B | +6.9% | $6.72 | $4.44–$7.96 | 15.3× | 12 |
| 2029 | $62.9B | +7.5% | $7.45 | $7.00–$7.58 | 13.8× | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-16 | $1.28 | $1.31 | +2.3% |
| 2026-04-16 | $1.14 | $1.15 | +0.9% |
| 2026-01-22 | $1.50 | $1.50 | +0.0% |
| 2025-10-15 | $1.30 | $1.30 | +0.0% |
| 2025-07-17 | $1.26 | $1.26 | +0.0% |
| 2025-04-16 | $1.07 | $1.09 | +1.9% |
| 2025-01-22 | $1.34 | $1.34 | +0.0% |
| 2024-10-16 | $1.20 |
| $1.21 |
| +0.8% |
| $120.1B |
| — |
| MRKMerck & Co., Inc. | $144.84 | +0.63% | $357.7B | — |
| NVONovo Nordisk A/S | $43.45 | +0.88% | $192.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Abbott Laboratories reached a $385 million settlement with the U.S. Department of Justice, resolving False Claims Act allegations related to powdered infant formula produced at its Sturgis, Michigan, and Casa Grande, Arizona, facilities between 2018 and 2022. The agreement includes approximately $348.7 million for the federal government and $36.3 million for certain states over Medicaid-related claims. Importantly, Abbott admitted neither wrongdoing nor liability, which investors viewed as a clean resolution of a long-standing legal overhang. With the liability now quantified and largely settled, the stock gained despite a weak broader market, reaching an intraday high of $104.44 before stabilizing. The company-specific catalyst comes ahead of Abbott’s next earnings report, expected in mid-October. The broader S&P 500 fell 0.3%, the Dow 0.1% and the Nasdaq 0.3%, highlighting that ABT’s move was driven primarily by the settlement rather than sector or market strength. $ABT
View on StockTwits ↗
$ABT Abbott to pay $385M to settle claims over 2022 infant formula recall
View on StockTwits ↗$ABBV $JNJ $ABT taking some profits.... Fed's coming wed... and it won't be good news for bulls !!
View on StockTwits ↗
$NMTC Our fiscal Q3 results demonstrated progress not only in product revenue, but also in the underlying economics of our commercial business. Product gross profit increased 29% year over year to $1.2 million, while product gross margin reached a record 59.9%, compared with 53.9% during the same period last year. The improvement reflected a more favorable product mix, while higher OneRF® product sales were the primary driver of revenue growth. Together with our ISO 13485 certification, these results strengthen the foundation supporting continued product adoption and our plans to selectively pursue international commercial opportunities. $ABT $MDT $GMED
View on StockTwits ↗
$ABT RSI is now at 24, & we have entered oversold territory. Next support for us should be around $100.68 or so, & that could be a very good spot for an entry for any who has the cash ready & waiting. Regardless, my gut tells me that the Exact Sciences integration will continue to be going well, & that earnings will once again be solid next month. We are still alive for $120+, perhaps even close to $130 by year end? Let's collect the dividend & be rewarded for our patience in the meantime. Look forward to seeing what happens, & how it all unfolds for us between now & year-end 🥂
View on StockTwits ↗
Don't forget that there is also an important settlement to watch for $ABT We have every detail, including how investors can get paid: https://11th.com/cases/abbott-investor-settlement
View on StockTwits ↗
$BSX Yesterday’s guidance cut wasn't an unpredictable event; it was the textbook resolution of an open liability. Truth is, markets have a ruthless way of punishing echo chambers. Too many traders mistake objective risk analysis for hostility. The person laying out an uncomfortable downside scenario isn't your adversary... they're handing you the blind spots you couldn't see from inside your position. If your thesis can't survive forensic scrutiny from an opposing view, it isn't a thesis; it's a bias. 40 yrs in this business teaches you to respect risk over narrative every time. Never dismiss the counter-argument that challenges your comfort zone, because the day you stop listening to the other side of the trade is the day the market humbles you. $SYK $MDT $ABT $ISRG
View on StockTwits ↗
$ABT sold additional puts today.. 10/23 with a 103 strike. If everything gets assigned, I will be stacked in ABT.. good thing there's a dividend 😄
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.